Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A display substrate according to the embodiment includes a base material containing chromium and iron, wherein the base material includes a surface portion and a central portion, the surface portion is defined as a depth region from a surface of the base material to a depth of 5 nm in a thickness direction of the base material, and a ratio of chromium atoms to iron atoms (Cr/Fe) of the surface portion is greater than that of the central portion.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

Abstract: A display apparatus and a controlling method thereof are provided. The display apparatus may include: a display panel that displays a screen; a light source disposed at one side of the display panel; an audio input that receives an audio signal; and a processor that flickers the light source in response to the received audio signal.

Abstract: This application relates to a method and system for cutting a brittle body. In one aspect the method includes preparing a brittle body having a rotary shaft. The method may also include forming a scribing line by irradiating laser on the brittle body along a preset route by using a laser irradiation unit. The method may further include cutting the brittle body by bringing a vibration unit that vibrates at a preset frequency in contact with a first region of the brittle body, which is spaced apart from the scribing line.

Abstract: In an alloy metal plate according to an embodiment, diffraction intensity of a (111) plane of the alloy metal plate is defined as I (111), diffraction intensity of a (200) plane of the alloy metal plate is defined as I (200), diffraction intensity of a (220) plane of the alloy metal plate is defined as I (220), a diffraction intensity ratio of I (200) is defined by the following Equation 1, and a diffraction intensity ratio of I (220) is defined by the following Equation 2. At this time, the A is 0.5 to 0.6, the B is 0.3 to 0.5, and the value A may be larger than a value B. A=I(200)/{1(200)+I(220)+I(111)}??[Equation 1] The diffraction intensity ratio of I (220) is defined by the following Equation 2.

Abstract: Disclosed is a coating material for a coating layer of an injection mold, the coating material including 100 parts by weight of a resin composition and about 30 to 40 parts by weight of a curing agent. The resin composition includes an amount of about 40 to 50 wt % of a first acrylic resin, an amount of about 5 to 15 wt % of a second acrylic resin having a weight average molecular weight less than a weight average molecular weight of the first acrylic resin, an amount of about 10 to 15 wt % of a carbon component, an amount of about 0.5 to 2 wt % of a matting agent, an amount of about 0.1 to 0.3 wt % of a catalyst and an amount of about 20 to 35 wt % of a solvent, all the wt % are based on the total weight of the resin composition.

Abstract: The present disclosure relates to a resin composition for vehicle parts, a vehicle part manufactured using the resin composition, and a method of manufacturing the vehicle part. Ultra-high molecular weight siloxane and an inorganic filler are mixed with an alloy resin of polyamide and polyethylene at an optimal rate in order to improve friction resistance and wear resistance while maintaining excellent impact resistance and low hygroscopicity. When a vehicle part is manufactured using the resin composition, it is possible to eliminate the application of silicone-based oil or to remarkably reduce the amount of silicone-based oil that is used, whereby it is possible to reduce manufacturing costs. Furthermore, ingredients that are harmful to human beings, such as POM, are not included, whereby it is possible to improve the quality of air in a vehicle.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: A long-acting conjugate for brain targeting is disclosed. The long-acting conjugate includes a peptide for brain targeting and a physiologically active material. The long-acting conjugate contains a physiologically active material with improved durability and stability, which can pass through the blood-brain barrier (BBB) and comprises a physiologically active material. The long-acting conjugate for brain targeting including a peptide for brain targeting and a physiologically active material can pass through the blood-brain barrier, thus enabling the treatment of diseases associated with brain diseases, and additionally, can maintain the activity of a physiologically active material in vivo and increase its half-life in the blood.

Abstract: A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

Abstract: A virtual reality experience apparatus includes: a displaying device configured to provide an experiencing user with a virtual reality image; and a riding device configured to provide the experiencing user with a motion, wherein the riding device includes: a riding part providing the experiencing user with a ridable space, and a gyro mechanism generating a pitching motion and a rolling motion of the riding part, wherein the gyro mechanism includes: a base structure having a pair of support columns disposed apart from each other, a pitching mechanism rotatably mounted on the pair of support columns to be rotated with respect to a pitching axis extending between the pair of support columns, and a rolling mechanism rotatably mounted on the pitching mechanism to be rotated with respect to a rolling axis perpendicular to the pitching axis.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A virtual reality experience apparatus includes: a displaying device configured to provide an experiencing user with a virtual reality image; and a riding device configured to provide the experiencing user with a motion, wherein the riding device includes: a riding part providing the experiencing user with a ridable space, and a gyro mechanism generating a pitching motion and a rolling motion of the riding part, wherein the gyro mechanism includes: a base structure having a pair of support columns disposed apart from each other, a pitching mechanism rotatably mounted on the pair of support columns to be rotated with respect to a pitching axis extending between the pair of support columns, and a rolling mechanism rotatably mounted on the pitching mechanism to be rotated with respect to a rolling axis perpendicular to the pitching axis.

Abstract: The present disclosure relates to a resin composition for vehicle parts, a vehicle part manufactured using the resin composition, and a method of manufacturing the vehicle part. Ultra-high molecular weight siloxane and an inorganic filler are mixed with an alloy resin of polyamide and polyethylene at an optimal rate in order to improve friction resistance and wear resistance while maintaining excellent impact resistance and low hygroscopicity. When a vehicle part is manufactured using the resin composition, it is possible to eliminate the application of silicone-based oil or to remarkably reduce the amount of silicone-based oil that is used, whereby it is possible to reduce manufacturing costs. Furthermore, ingredients that are harmful to human beings, such as POM, are not included, whereby it is possible to improve the quality of air in a vehicle.